×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
FibroGen, Kind Pharma settle trade secrets theft dispute
Fierce Pharma
FibroGen originally sued Liu and Deng in December 2022 for allegedly pinching proprietary information and filing improper patents around hypoxia...
1 month ago
FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript
Yahoo Finance
FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript May 6, 2024 FibroGen, Inc. misses on earnings expectations.
2 weeks ago
AstraZeneca Returns to FibroGen the Rights to Roxadustat in US, Other Territories
BioSpace
AstraZeneca Returns to FibroGen the Rights to Roxadustat in US, Other Territories ... AstraZeneca on Monday shut down the bulk of its roxadustat...
2 months ago
FibroGen to Participate in Upcoming Investor Conferences
GlobeNewswire
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company's management will participate...
2 weeks ago
Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet
Simply Wall Street
Unfortunately for some shareholders, the FibroGen, Inc. ( NASDAQ:FGEN ) share price has dived 28% in the last thirty...
2 weeks ago
Prostate cancer ADC breaks FibroGen's clinical losing streak
Fierce Biotech
A phase 1 study of the anti-CD46 antibody drug conjugate (ADC) FG-3246 in 56 patients with metastatic castration-resistant prostate cancer...
1 month ago
FibroGen's $28.5 Million Deal With Investors Gets First Approval
Bloomberg Law News
FibroGen Inc.'s agreement to pay a class of shareholders $28.5 million to settle a stock-drop suit over an anemia drug merits preliminary...
3 months ago
FibroGen's $28.5M Deal With 30K Investors Nears Tentative OK
Law360
A California federal judge indicated Wednesday that he'll preliminarily sign off on a $28.5 million settlement secured for a class of...
3 months ago
Akebia defends anaemia drug patents at EPO amid huge Fibrogen battle
JUVE Patent
EPO for Akebia. Akebia Therapeutics is involved in an ongoing patent dispute with Fibrogen concerning vadadustat. The company alleges that...
2 months ago
FibroGen Reports First Quarter 2024 Financial Results
Yahoo Finance
Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer...
2 weeks ago